Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.84 |
| ▸ | HTT | P42858 | 4/20 | 0.84 |
| ▸ | HAT1 | O14929 | 4/20 | 0.84 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.84 |
| ▸ | USP2 | O75604 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 3/20 | 0.54 |
| ▸ | CASP7 | P55210 | 3/20 | 0.54 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TST | Q16762 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HBB | P68871 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31029223 | 1.00 | MEN1 (0.84) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL15908042 | 0.97 | MEN1 (0.79) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL15909982 | 0.96 | MEN1 (0.80) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL29940644 | 0.91 | MEN1 (1.00) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL22711765 | 0.91 | MEN1 (1.00) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL182062 | 0.91 | MEN1 (1.00) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL30113081 | 0.91 | MEN1 (1.00) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL182061 | 0.91 | MEN1 (1.00) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL15908089 | 0.91 | MEN1 (0.81) | MEN1KMT2AHTTHAT1RBBP7 | |
| SCHEMBL31029204 | 0.88 | MEN1 (0.88) | MEN1KMT2AHTTHAT1RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-4637775-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS Therapeutics LLC (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-119185313-A | Leishmod prodrug, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-12-27 | — | — | CN | claimed |
| WO-2024137921-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2024-06-27 | — | — | WO | claimed |
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4637775-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS Therapeutics LLC (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025131038-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF PHARMACEUTICAL ACTIVES | ADS THERAPEUTICS LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119185313-A | Leishmod prodrug, and preparation method and application thereof | 中国科学院长春应用化学研究所 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024137921-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | ADS THERAPEUTICS LLC (US) | 2024-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144875-A1 | COMPOSITIONS AND METHODS FOR CROSSLINKING STRUCTURAL PROTEINS | STRA6, RBP4, F12 | MEN1 4816/4885KMT2A 4211/4885HTT 2084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.